Human PilotPubMed ID: 38429187·2024

Retatrutide reduces appetite ratings and neural activation in appetite centers

Ochner CN, Barker EN, Melanson EL, et al.

International Journal of Obesity, 2024 · n = 32

Key finding

Retatrutide reduced activation in nucleus accumbens and lateral orbitofrontal cortex (p=0.014) and decreased self-reported hunger by 6.2 ± 1.1 points vs 0.3 ± 1.3 placebo.

Summary

fMRI study examining neural responses to food images and appetite-related questionnaires in obese subjects receiving retatrutide versus placebo.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

RetatrutideL4

A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.

More research on Retatrutide

TRIUMPH-NAS: Retatrutide for Non-Alcoholic Steatohepatitis

Journal of Hepatology · 2025 · Human RCT

TRIUMPH-OA: Retatrutide for Obesity-Related Osteoarthritis

Osteoarthritis and Cartilage · 2025 · Human RCT

Genetic Polymorphisms Predict Retatrutide Response: GWAS Analysis

Cell Metabolism · 2025 · Human RCT

Comparative Efficacy: Retatrutide vs Tirzepatide in Randomized Head-to-Head Trial

New England Journal of Medicine · 2025 · Human RCT

TRIUMPH 1: Retatrutide versus Placebo in Obesity (Phase 3)

Lancet Diabetes & Endocrinology · 2024 · Human RCT